lapatinib has been researched along with Exanthem in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ayanoglu, BT; Demirdag, HG; Yalici-Armagan, B | 1 |
| Dranitsaris, G; Lacouture, ME | 1 |
| Agbor-Tarh, D; Azim, HA; Boyle, F; Bradbury, I; Campbell, C; de Azambuja, E; Dueck, AC; Gomez, H; Huang, Y; Jackisch, C; Lang, I; Perez, EA; Piccart, M; Pritchard, KI; Smith, I; Sonnenblick, A; Untch, M; Wolff, AC; Xu, B | 1 |
| Gao, B; Guo, L; Hao, S; Hu, C; Jiang, Y; Luo, D; Tian, W; Yan, J; Zhang, G; Zhang, S; Zhang, X; Zhao, J | 1 |
| Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW | 1 |
| Blaney, SM; Boyett, JM; Fouladi, M; Gajjar, A; Gilbertson, RJ; Kun, LE; Onar-Thomas, A; Packer, RJ; Schaiquevich, P; Stewart, CF | 1 |
| Gerami, P; Guitart, J; Lacouture, ME; Nardone, B; Newman, M; Nicholson, K; Rademaker, A; Talarico, N; West, DP; Yang, XJ | 1 |
| Chi, HD; Chua, D; Jiang, ZF; Liu, DG; Luo, RC; Martin, AM; Newstat, B; Preston, A; Shao, ZM; Wang, L; Wang, XJ; Xu, BH; Yeo, W; Yu, SY | 1 |
| Berrier, A; Biswas-Baldwin, N; Compton, N; de Mendoza, FH; El-Hariry, I; Fayette, J; Franklin, N; Harrington, K; Housset, M; Kumar, R; Lau, M; Legenne, P; Mehanna, H; Remenar, E; Robinson, M | 1 |
2 review(s) available for lapatinib and Exanthem
| Article | Year |
|---|---|
Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Factors; Trastuzumab; Treatment Outcome; Withholding Treatment | 2017 |
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines; Skin Diseases; Treatment Outcome | 2009 |
5 trial(s) available for lapatinib and Exanthem
| Article | Year |
|---|---|
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Models, Biological; Quinazolines; Risk Factors; ROC Curve; Skin Neoplasms | 2014 |
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Eruptions; Exanthema; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Survival Rate; Time Factors; Trastuzumab; Treatment Outcome | 2016 |
Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Central Nervous System Neoplasms; Child; Child, Preschool; Diarrhea; ErbB Receptors; Exanthema; Fatigue; Female; Humans; Infant; Lapatinib; Male; Maximum Tolerated Dose; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Steroids; Treatment Outcome; United States; Young Adult | 2010 |
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Exanthema; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Remission Induction | 2011 |
Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Diarrhea; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Exanthema; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lapatinib; Male; Middle Aged; Neoplasm Staging; Papillomaviridae; Quinazolines; Radiotherapy Dosage; Treatment Outcome | 2013 |
2 other study(ies) available for lapatinib and Exanthem
| Article | Year |
|---|---|
Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Panitumumab; Pruritus; Retrospective Studies | 2019 |
Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atrophy; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Immunohistochemistry; Keratin-16; Lapatinib; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Skin; Young Adult | 2010 |